

The Wall Street Journal news department was not involved in the creation of this content.

PRESS RELEASE | November 4, 2013, 1:35 a.m. ET

## Eurofins: Sustained Growth Momentum Bodes Well for the Full Year 2013

- Revenues increased over 17% year-on-year to EUR 882m.
- Organic growth of over 6% as momentum remains strong across most markets. Excluding businesses that are in significant restructuring, organic growth stood at 7.5%.
- Strong performance across most areas of our business.

LUXEMBOURG-- (BUSINESS WIRE)--November 04, 2013--

### Regulatory News:

Comments from the CEO, Dr. Gilles Martin: "The results achieved year to date reflect the strength that we have built into our network. We have the ability to invest in projects that may be dilutive in the near-term, but create significant long-term value. The impact of these investments is offset by the strong performance in the majority of the Group's businesses. Despite the ongoing economic uncertainty in Europe, and the temporary impact of our businesses that are in restructuring, organic growth remains above our objective. We therefore remain confident that we should be able to achieve our objectives for the full year 2013."

9M 2013 EURm	9M 2013	9M 2012	% Growth
-----	-----	-----	-----
Eurofins Group Revenues	882.2	751.1	17.5%
-----	-----	-----	-----

Eurofins (Paris:ERF) generated revenues of EUR 882.2m during the first nine months of the year, representing growth of 17.5%. Organic growth was over 6%, currency translation had a negative impact of 1.6%, and the remainder came from acquisitions. Adjusted for businesses in significant restructuring, organic growth was 7.5%.

The Group's continued strong performance reflects both the attractive fundamentals of its businesses, and the benefits of its leading position in most of the markets it serves. Robust growth in food testing is driven by the increasing focus on risk management across the food supply chain, regulation, and Eurofins' entry into new markets. Pharmaceutical testing delivered solid growth driven by continued strength in pharmaceutical products testing and genomics, offsetting the temporary impact of reorganization in the Group's central laboratory and discovery pharmacology businesses.

Environmental testing continues to be impacted by the IPL restructuring in France, and overall slower environmental testing activities in Europe.

The US and Germany (23% and 17% of Group revenues respectively), both delivered strong organic growth of 10% in the first nine months, driven by market growth and expansion in Eurofins' market share. In France, the impact of the ongoing IPL reorganization was offset by the continued strong performance in food testing. The double-digit organic growth in the UK (5% of revenues) came on the back of an outsourcing contract, and to a lesser extent, the horsemeat scandal. The Nordic countries have had stronger growth in Q2 and Q3 following the weather-related slower start to the year. Finally, strong growth in emerging markets and Asia Pacific continues to expand these regions' share of Group revenues.

For more information, please visit [www.eurofins.com](http://www.eurofins.com)

Notes for the editor:

Eurofins -- a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics, discovery pharmacology and central laboratory services.

With over 14,500 staff in more than 190 laboratories across 37 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.

CONTACT: Eurofins Investor Relations

Phone: +32-2-766 1620

E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

SOURCE: Eurofins  
Copyright Business Wire 2013

Order free Annual Report for Eurofins Scientific SE

Visit <http://djnweurope.ar.wilink.com/?ticker=FR0000038259> or call +44 (0)208 391 6028